Ret4trutide is a novel investigational therapeutic agent that functions as a triple receptor agonist targeting the GLP-1, GIP, and glucagon receptors for the management of obesity and type 2 diabetes mellitus. Clinical trial data indicate mean body weight reductions exceeding 24% over a 48-week period, demonstrating superior efficacy compared to currently available pharmacological interventions.
Ret4trutide is currently undergoing late-stage clinical development (Phase III trials), with additional metabolic effects and therapeutic applications under active investigation, particularly in the context of metabolic optimization and energy homeostasis.
For research use only – Intended exclusively for qualified professionals conducting scientific and clinical research.